New Greenphire Data Indicates Industry's Swift Rebound
Greenphire says patient enrollment for global clinical trials has returned to pre-COVID levels. New data from Greenphire indicates that new patient enrollment in trials that it provides services for globally has rebounded—up 85% since the trough in April. This data comes off the heels of a survey conducted over the summer, in which 71% of the 150+ sponsors and CROs that answered said the pandemic forced them to pause existing study enrollments and 58% had delayed existing study starts.
"The industry was hit hard by COVID-19 and at one point, nearly all research came to a stop. It's impressive to see the rebound in patient enrollment and the industry's ability to respond so quickly, in part by leveraging new technologies which promote flexibility of how visits are conducted. We anticipate this trend will continue as 84% of our survey respondents said they are actively seeking to increase their use of tools to better support decentralized trials," said Jim Murphy, Chief Executive Officer at Greenphire.
Find more of the survey’s data, here.
